Are you familiar with that moment of hesitation when facing a critical decision, knowing that much is at stake and time is of the essence?
This daily challenge is particularly acute for pathologists and oncologists worldwide, especially when making treatment decisions for cancer patients. A minor error in judgment can have far-reaching consequences on numerous lives.
To support pathologists and oncologists in these critical decisions, we have developed Ai Copilot applications.
These tools assist in decision-making, biomarker quantification, and prognosis prediction, utilizing AI technology and histology slides across various cancers such as breast cancer, melanoma, and more.
With our unique holistic approach, we provide real-time insights that empower pathologists and oncologists, facilitating and securing their decision-making processes.
Back from #PathVisions (Digital Pathology Association) in Orlando and it's time for a wrap. It was an incredible opportunity filled with meaningful encounters and discussions on digital pathology and artificial intelligence. Thank you to everyone who took the time to discuss DiaDeep’s solutions, share your enthusiasm, and engage in the shared passion for advancing diagnostic accuracy and patient care. We return inspired by your insights and more motivated than ever to continue developing tools that support pathologists and oncologists in their daily practice.
🚀 Day 3 of #Pathvisions Congress in Orlando!
It's been an eye-opening experience hearing directly from pathologists about the real challenges they face day-to-day. From long hours to the pressure of ensuring precise diagnoses, the work is demanding, and any tool that can help ease that burden is a game-changer.
One technology that has sparked so much excitement is DiaDeep’s PDL1 CPS AI. Pathologists have shared how challenging and time-consuming it is to assess PDL1 expression accurately and consistently. It’s a task that requires immense focus and can often lead to variability between cases. With AI stepping in, we’re not replacing their expertise but empowering them — helping them speed up the process without compromising accuracy.
The goal? To give pathologists more time to focus on the bigger picture: patient care. By reducing the mental load and ensuring more consistent results, AI allows them to make faster, more confident decisions, all while keeping their workflow manageable and precise.
Day 2 at #PathVisions24 in Orlando. Come and meet with DiaDeep team about our innovative approach in AI. You’re tired of doing your #PDL1 CPS/TPS, Ki67, ER/PR, HER2 or mitosis counts? Come and chat with Baptiste GOURDIN and Yahia SALHI about our 0-click, 0 intervention and agnostic AI tools! No matter what IMS you’re using, we can help you! See you t booth #105! 👀
Because every decision counts, and every patient matters, we at DiaDeep understand the challenges you face with PD-L1 scoring and the critical decisions that follow. Kwant™ PD-L1 AI #CPS and #TPS scoring was created to ease the burden of tedious quantifications, giving you more confidence in your results.
Join us at #PathologyVisions (Digital Pathology Association), where we’ll be sharing the largest pan-organ PD-L1 retrospective study conducted using AI, developed and validated alongside 8 pathology institutions.
As always, all DiaDeep solutions are 0 CLICK including PD-L1!
Excited to welcome Pascal to the DiaDeep team as Chief Customer Officer! With his expertise and shared dedication to enhancing cancer diagnostics, we’re looking forward to the impact he’ll bring to our mission of supporting pathologists and oncologists and improving patient care. Welcome aboard, Pascal!
🚀 Thrilled to share the next chapter in my journey – I decided to join DiaDeep as Chief Customer Officer! 🚀
I’m beyond excited to be part of a customer-centric company that’s pushing the boundaries of AI-driven pathology and transforming healthcare through cutting-edge quantitative, prognostics, and theranostics solutions.
In my role, I’ll be dedicated to leading DiaDeep’s customer-first approach, empowering our clients to harness the full potential of AI to revolutionize patient diagnostics and care. Together with an incredible and talented team, I’ll work to ensure that our tools are seamlessly integrated into clinical workflows, driving impactful insights for pathologists, healthcare providers, and researchers worldwide.
💡 If you’re interested in the powerful intersection of AI and healthcare or want to partner with DiaDeep on our mission to transform patient outcomes, let’s connect!
----
🚀 Je suis heureux de vous partager la prochaine étape de mon parcours – J’ai décidé de rejoindre DiaDeep en tant que Chief Customer Officer ! 🚀
Je suis plus que ravi de faire partie d’une entreprise humaine et centrée sur le client qui repousse les limites de la pathologie propulsée par l’IA et qui transforme les soins de santé grâce à des solutions quantitatives, pronostiques et théranostiques de pointe.
Dans mon rôle, je me consacrerai à diriger l’approche axée sur le client de DiaDeep, afin d’exploiter tout le potentiel de l’IA permettant de révolutionner le diagnostic et les soins aux patients. En collaboration avec une équipe de qualité et incroyable, je veillerai à ce que nos outils soient parfaitement intégrés aux flux de travail cliniques, apportant des informations percutantes aux pathologistes, aux prestataires de soins de santé et aux chercheurs du monde entier.
💡 Si vous êtes intéressé par la puissante convergence entre IA et la santé ou que vous souhaitez collaborer avec DiaDeep dans notre mission de transformation des soins aux patients, contactez moi!
Ce contenu n’est pas disponible ici
Accédez à ce contenu et plus encore dans l’application LinkedIn
Struggling with PD-L1 CPS scoring? What about taking it to the next level using AI?
We’ll be sharing DiaDeep results this year at #PathologyVisions Congress, the largest PD-L1 retrospective study ever conducted using AI, developed and validated in collaboration with 8 pathology institutions.
At DiaDeep, we understand the challenges you face with PD-L1 quantification and the critical decisions that follow. Kwant PD-L1 AI scoring was created to ease the burden of tedious quantifications, giving you more confidence in your results.
As always, all DiaDeep solutions are 0 CLICK including PD-L1!
Because every decision counts, and every patient matters.
🗓️ 3-5 November
📢 I am recruiting (senior) data scientists. If you know someone who knows someone who is looking to join DiaDeep’s mission to transform cancer diagnostics and improve patients outcomes, l’d appreciate the introduction ! Drop me a DM.
🚀 DiaDeep Simplifies AI Adoption with Kwant Breast Integration to Sectra’s Digital Pathology Solution 🚀
💡 What this means for our customers:
✅ No more disruptions to your Workflow
DiaDeep fully integrates with Sectra supporting a wide range of scanners for easy adoption.
✅ No more manual Region Selection
Our fully automated algorithms handle the entire biomarker scoring process—just scan and view accurate results instantly.
✅ Eliminate tedious Quantification Tasks
Say goodbye to manual quantification. DiaDeep delivers hands-free, immediate biomarker scoring, freeing you to focus on critical decisions.
✅ No need to worry about variability
DiaDeep ensures consistent biomarker scoring accuracy across all slides, regardless of lab-specific factors.
We owe it to the breast pathology experts from various labs! Kwant Ki67, ER, PR, and HER2 were created thanks to the meticulous work of pathologists who carefully annotated each cell for accurate scoring. Our data scientists then transformed this into a tool designed to support your diagnostic journey.
👉 Discover more about our integration: Visit DiaDeep on Sectra Amplifier Marketplace :
https://lnkd.in/eHFwPNzU
